Cancer Chemotherapy and Pharmacology

, Volume 64, Issue 4, pp 647–655 | Cite as

Temozolomide in malignant gliomas: current use and future targets

  • J. Lee Villano
  • Tara E. Seery
  • Linda R. Bressler
Mini Review


Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance.


Temozolomide Brain tumor Alkylating chemotherapy Malignant glioma Glioblastoma Tumor resistance 


  1. 1.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  2. 2.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRefGoogle Scholar
  3. 3.
    CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000–2004. In: Edition Published by the Central Brain Tumor Registry of the United States 2008Google Scholar
  4. 4.
    Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedCrossRefGoogle Scholar
  5. 5.
    Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597PubMedCrossRefGoogle Scholar
  6. 6.
    Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88PubMedCrossRefGoogle Scholar
  7. 7.
  8. 8.
    Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382PubMedCrossRefGoogle Scholar
  9. 9.
    Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593PubMedCrossRefGoogle Scholar
  10. 10.
    Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  11. 11.
    Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRefGoogle Scholar
  12. 12.
    Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569PubMedCrossRefGoogle Scholar
  13. 13.
    Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354PubMedCrossRefGoogle Scholar
  14. 14.
    Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
  15. 15.
    Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535PubMedCrossRefGoogle Scholar
  16. 16.
    Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214PubMedCrossRefGoogle Scholar
  17. 17.
    Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRefGoogle Scholar
  18. 18.
    Kimple RJ, Grabowski S, Papez M et al (2008) Glioblastoma in the elderly: radiation, chemoradiation, and supportive care. J Clin Oncol 26 (abstr 20738)Google Scholar
  19. 19.
    Baker SD, Wirth M, Statkevich P et al (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309–317PubMedGoogle Scholar
  20. 20.
    Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61PubMedCrossRefGoogle Scholar
  21. 21.
    Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295–2305PubMedCrossRefGoogle Scholar
  22. 22.
    Marchesi F, Turriziani M, Tortorelli G et al (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275–287PubMedCrossRefGoogle Scholar
  23. 23.
    Kanzawa T, Bedwell J, Kondo Y et al (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99:1047–1052PubMedCrossRefGoogle Scholar
  24. 24.
    Roos WP, Batista LF, Naumann SC et al (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186–197PubMedCrossRefGoogle Scholar
  25. 25.
    Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493–500PubMedCrossRefGoogle Scholar
  26. 26.
    Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011PubMedCrossRefGoogle Scholar
  27. 27.
    Balmaceda C, Peereboom D, Pannullo S et al (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112:1139–1146PubMedCrossRefGoogle Scholar
  28. 28.
    Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11:69–79PubMedCrossRefGoogle Scholar
  29. 29.
    Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733–740PubMedCrossRefGoogle Scholar
  30. 30.
    Kim JT, Kim JS, Ko KW et al (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33–39PubMedGoogle Scholar
  31. 31.
    Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515–522PubMedCrossRefGoogle Scholar
  32. 32.
    Lee SM, Brada M, Stenning S, Thompson L, Gabe R (2008) A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12 ISRCTN83176944). Ann Oncol 19:viii2 (LBA 5)CrossRefGoogle Scholar
  33. 33.
    Rabik CA, Njoku MC, Dolan ME (2006) Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32:261–276PubMedCrossRefGoogle Scholar
  34. 34.
    Turriziani M, Caporaso P, Bonmassar L et al (2006) O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res 53:317–323PubMedCrossRefGoogle Scholar
  35. 35.
    Broniscer A, Gururangan S, MacDonald TJ et al (2007) Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718PubMedCrossRefGoogle Scholar
  36. 36.
    Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187PubMedCrossRefGoogle Scholar
  37. 37.
    Ranson M, Middleton MR, Bridgewater J et al (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577–1584PubMedCrossRefGoogle Scholar
  38. 38.
    Khan OA, Ranson M, Michael M et al (2008) A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98:1614–1618PubMedCrossRefGoogle Scholar
  39. 39.
    Ranson M, Hersey P, Thompson D et al (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25:2540–2545PubMedCrossRefGoogle Scholar
  40. 40.
    Miknyoczki S, Chang H, Grobelny J et al (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290–2302PubMedCrossRefGoogle Scholar
  41. 41.
    Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728–2737PubMedCrossRefGoogle Scholar
  42. 42.
    Ganiere V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339–343 (quiz following 343)PubMedCrossRefGoogle Scholar
  43. 43.
    FDA (2007) Temozolomide (marketed as Temodar): aplastic anemia. Drug Saf Newsl 1:7Google Scholar
  44. 44.
    Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a Phase II trial. J Clin Oncol 23 (abstract #1546)Google Scholar
  45. 45.
    Jalali R, Singh P, Menon H, Gujral S (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 85:105–107PubMedCrossRefGoogle Scholar
  46. 46.
    Morris B, Reiss U, Kasow K, Broniscer A (2008) Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM). Neuro Oncol 10:396 (abstract CR2)Google Scholar
  47. 47.
    Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature. J Neurooncol 85:229–230PubMedCrossRefGoogle Scholar
  48. 48.
    Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438PubMedCrossRefGoogle Scholar
  49. 49.
    Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47–52PubMedCrossRefGoogle Scholar
  50. 50.
    Noronha V, Berliner N, Ballen KK et al (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 8:280–283PubMedCrossRefGoogle Scholar
  51. 51.
    Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 71:315–318PubMedCrossRefGoogle Scholar
  52. 52.
    Chamberlain MC, Glantz MJ, Chalmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83PubMedCrossRefGoogle Scholar
  53. 53.
    Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410PubMedCrossRefGoogle Scholar
  54. 54.
    Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197PubMedCrossRefGoogle Scholar
  55. 55.
    Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508PubMedGoogle Scholar
  56. 56.
    Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180–188PubMedCrossRefGoogle Scholar
  57. 57.
    Gerstner ER, McNamara MB, Norden AD et al (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol [Epub ahead of print]Google Scholar
  58. 58.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  59. 59.
    Quan D, Hackney DB, Pruitt AA et al (1999) Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 53:211–213PubMedGoogle Scholar
  60. 60.
    Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347PubMedCrossRefGoogle Scholar
  61. 61.
    Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688–690PubMedCrossRefGoogle Scholar
  62. 62.
    Stupp R, Hottinger AF (2008) Management of malignant glioma—quo vadis? Onkologie 31:300–302PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • J. Lee Villano
    • 1
  • Tara E. Seery
    • 1
  • Linda R. Bressler
    • 2
  1. 1.Section of Hematology/Oncology, Department of MedicineUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of Pharmacy PracticeUniversity of Illinois at ChicagoChicagoUSA

Personalised recommendations